API | quizartinib

quizartinib Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Quizartinib (AC220) is a small molecule receptor tyrosine kinase inhibitor, originally from Ambit Biosciences and later acquired by Daiichi Sankyo, that is currently under development for the treatment of acute myeloid leukaemia. Quizartinib is sold under the brand name Vanflyta in Japan. Its molecular target is FLT3, also known as CD135 which is a proto-oncogene. ^Wikipedia

Chemistry

SMILES: CC(C)(C)c1onc(NC(=O)Nc2ccc(cc2)c3cn4c5ccc(OCCN6CCOCC6)cc5sc4n3)c1
InChIKey: CVWXJKQAOSCOAB-UHFFFAOYSA-N
Mol. Mass: 560.68
ALogP: 5.86 Partition coefficient
ChEMBL Molecules:

quizartinib

quizartinib dihydrochloride

More Chemistry

Pharmacology

Mechanisms of Action:
- Macrophage colony-stimulating factor 1 receptor (Homo sapiens) ^UniProt
- Platelet-derived growth factor receptor alpha (Homo sapiens) ^UniProt
- Platelet-derived growth factor receptor beta (Homo sapiens) ^UniProt
- Mast/stem cell growth factor receptor Kit (Homo sapiens) ^UniProt
- Receptor-type tyrosine-protein kinase FLT3 (Homo sapiens) ^UniProt
- Proto-oncogene tyrosine-protein kinase receptor Ret (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

ac010220 | ac010220.2hcl | ac220 | ac-220 | ac220 compound | asp-2689 | quizartinib | quizartinib dihydrochloride

Organizations (19)

Research & Development (19)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (15)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (15)

Biomarkers (Phase 2)

Bone Marrow Cells (Phase 2)

Drug Interactions (Phase 1)

Drugs, Investigational (Phase 1)

Healthy Volunteers (Phase 1)

Leukemia (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Leukemia, Myelomonocytic, Chronic (Phase 2)

Liver Diseases (Phase 1)

Mutation (Phase 2)

Myelodysplastic Syndromes (Phase 3)

Myeloproliferative Disorders (Phase 2)

Neoplasms (Phase 1)

Pharmacokinetics (Early Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 35
# of Trial Organizations: 19

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue